Fig. 4. Infection outcome after early treatment with ART and VES.
a Treatment with FTC/TAF/CAB LA/RPV LA was initiated at day 6/8 post-infection and treatment with VES at day 8/11. FTC/TAF/CAB LA/RPV LA was administered for 4 months and VES for 3 months. Transient CD8 depletion was done 16 months after treatment initiation (or 12 months after treatment discontinuation). b Area under the curve values for SHIV RNA (AUC0-19days) in untreated controls (red) and macaques treated with eART only (blue) and eART + VES (green). Each data point reflects AUC values seen in one macaque. AUC0-19days values were similar among macaques in the eART + VES and eART-only groups (p = 0.686; two-sided Wilcoxon Rank Sum test). c SHIV infection dynamics during treatment and after discontinuation. The four untreated controls are shown in red for comparison. d SHIV plasma IgG levels against gp140 during acute infection in macaques treated with eART + VES (individual animals in light green; dark green denotes median), eART alone (individual animals in light blue; dark blue denotes median), and in two untreated controls (red lines). Source data are provided as a Source Data file.